Harnessing designed nanoparticles: Current strategies and future perspectives in cancer immunotherapy

Sung Duk Jo, Gi Hoon Nam, Gijung Kwak, Yoosoo Yang, Ick Chan Kwon

Research output: Contribution to journalReview articlepeer-review

69 Citations (Scopus)


Although cancer immunotherapy, represented by chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint-blockade therapies, has shown durable outcomes, the percentage of patients that respond to these approaches remains modest to date. However, encouraging recent advances suggest that nanotechnology has the potential to enhance the efficacy of such immunotherapies by improving the delivery, biodistribution, and release-kinetics of immunostimulatory small molecules and biologics in targeted tissues. A variety of synthetic nanoparticles, including polymeric nanoparticles, liposomes and inorganic nanoparticles, can be engineered according to their intended uses in cancer immunotherapy. Notably, nature-derived nanoparticles have emerged as a new class of immunotherapeutics. In this review, we describe state-of-the-art strategies for cancer immunotherapy using designed nanoparticles. We also highlight key translational challenges and opportunities in this rapidly growing field.

Original languageEnglish
Pages (from-to)23-37
Number of pages15
JournalNano Today
Publication statusPublished - 2017 Dec

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) funded by the Korea government [2017R1A2B2010292]; the KU-KIST Graduate School of Conversing Science and Technology Program; and the KIST institutional Program.

Publisher Copyright:
© 2017 Elsevier Ltd


  • Cancer immunotherapy
  • Drug delivery system
  • Exosome
  • Nanoparticles
  • Targeted delivery
  • Tumor immune evasion
  • Vaccines

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • General Materials Science
  • Pharmaceutical Science


Dive into the research topics of 'Harnessing designed nanoparticles: Current strategies and future perspectives in cancer immunotherapy'. Together they form a unique fingerprint.

Cite this